Impact of the ileal microbiota on colon cancer

Besides tumor cell-intrinsic oncogenic pathways, host and environmental factors have a major impact on cancer immunosurveillance and the efficacy of immunotherapeutics. Several modalities of anticancer treatments including immunogenic chemotherapies and immune checkpoint inhibitors lose their effica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Roberti, Maria Paula (VerfasserIn) , Rauber, Conrad (VerfasserIn) , Kroemer, Guido (VerfasserIn) , Zitvogel, Laurence (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 October 2022
In: Seminars in cancer biology
Year: 2022, Jahrgang: 86, Pages: 955-966
ISSN:1096-3650
DOI:10.1016/j.semcancer.2021.09.016
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.semcancer.2021.09.016
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1044579X21002509
Volltext
Verfasserangaben:Maria Paula Roberti, Conrad Rauber, Guido Kroemer, Laurence Zitvogel
Beschreibung
Zusammenfassung:Besides tumor cell-intrinsic oncogenic pathways, host and environmental factors have a major impact on cancer immunosurveillance and the efficacy of immunotherapeutics. Several modalities of anticancer treatments including immunogenic chemotherapies and immune checkpoint inhibitors lose their efficacy in patients treated with broad-spectrum antibiotics, pointing to a key role for the gut microbiota. The complex interactions between intestinal microbes, gut immunity and anti-tumor responses constitute an emerging field of investigation. In this work, we revise key primary literature, with an emphasis on recent mechanistic insights, unraveling the interplay between the immunosurveillance of colon cancers and ileal factors including the local microbiota, tissue architecture and immune system.
Beschreibung:Online verfügbar 5. Oktober 2021, Artikelversion 19. Oktober 2022
Gesehen am 07.06.2023
Beschreibung:Online Resource
ISSN:1096-3650
DOI:10.1016/j.semcancer.2021.09.016